Trends in antimicrobial susceptibility patterns in N. gonorrhoea in Australia: Systematic review and meta-regression analysis

Autor: S. Fletcher-Lartey, H. Lord, M. Dronavalli, K. Alexander, S. Ghosh, J. Thomas, A. Robinson, J. Sisnowski, N. Pal

Publikováno v: International Journal of Infectious Diseases, Vol 101, Iss , Pp 41- (2020)

Externí odkaz: https://doaj.org/article/5320a3a48d0841d8881cbe6cc7865bc5

Antiviral prophylaxis is effective in reducing influenza outbreak severity in residential care

Autor: M. Dronavalli, S. Fletcher-Lartey, H. Lord, L. Boonwaat, N. Pal, K. Alexander

Publikováno v: International Journal of Infectious Diseases, Vol 101, Iss , Pp 336- (2020)

Externí odkaz: https://doaj.org/article/7bb781cc34fc47dc869366628f0fbd86

Glycemic control level alters working memory neural dynamics in adults with type 2 diabetes

Autor: Christine M Embury, Grace H Lord, Andjela T Drincic, Cyrus V Desouza, Tony W Wilson

Publikováno v: Cerebral Cortex.

Poor glycemic control in type 2 diabetes has been associated with accentuated age-related cognitive decline, although the underlying neural mechanisms are not well understood. The current study sought to identify the impact of glycemic control on the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a03c7f2ae034121489d3af355201b56
https://doi.org/10.1093/cercor/bhad119

P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era

Autor: H. Lord, C. Douglas

Publikováno v: Journal of Thoracic Oncology

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6181b917e1c6a31091e776ea7f1ee243
https://doi.org/10.1016/j.jtho.2021.08.418

Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer

Autor: M, Stares, T E, Ding, C, Stratton, F, Thomson, M, Baxter, H, Cagney, K, Cumming, A, Swan, F, Ross, C, Barrie, K, Maclennan, S, Campbell, T, Evans, A, Tufail, S, Harrow, H, Lord, B, Laird, M, MacKean, I, Phillips

Publikováno v: Stares, M, Ding, T-E, Stratton, C, Thomson, F, Baxter, M, Cagney, H, Cumming, K, Swan, A, Ross, F, Barrie, C, Maclennan, K, Campbell, S, Evans, T, Tufail, A, Harrow, S, Lord, H, Laird, B J A, Mackean, M J & Phillips, I 2022, ' Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small cell lung cancer ', ESMO Open, vol. 7, no. 2, 100445 . https://doi.org/10.1016/j.esmoop.2022.100445

IntroductionPembrolizumab is an established first-line option for patients with advanced non-small-cell lung cancer (NSCLC) expressing programmed death-ligand 1 ≥50%. Durable responses are seen in a subset of patients; however, many derive little c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f055870768dd8c9243fd1deb2ba3d07
https://doi.org/10.1016/j.esmoop.2022.100445